- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01970670
Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer
Contrast-Enhanced Digital Mammography (CEDM) vs Contrast-Enhanced Breast MRI (CE-MRI) in Patients With Known Breast Cancer
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Identify inclusion criteria
- Histologically confirmed invasive and/or in situ carcinoma of the breast
- Any race and ethnicity
- Females 18-70 years of age
- Willing and able to provide informed consent
- Subject will have a CE-MRI exam within one month (31 days) of enrolling or has had a CE-MRI exam within one month (31 days) prior to enrolling with no interval treatment or procedure between the CEDM and CE-MRI
Identify exclusion criteria
- Unwilling or unable to undergo informed consent
- Planned to undergo neoadjuvant chemotherapy
- Breast implants
- Pregnant (NOTE: If subject is unsure of pregnancy status, a pregnancy test will be performed for confirmation.)
- Breast-feeding
- Surgical excision of the biopsy proven malignancy
- Known allergy to gadolinium contrast agents
- Contraindication for MRI (ex: pacemaker, ferromagnetic aneurysm clips or other ferromagnetic surgical implant or severe claustrophobia)
Suspected to be at risk to complications from the contrast agent. These include the standard iodinated contrast agent contraindications:
- Subject has renal insufficiency as determined by an elevated serum creatinine and is not being treated with dialysis.
- Documentation of a normal eGFR (MDRD) within the previous 2 months will be required for any subject with any of the following risk factors for renal insufficiency:
i. Age > 70 ii. Diabetes iii. Personal history of renal disease iv. Family history of renal disease (e.g., polycystic kidney disease) v. Known solitary kidney vi. Other medical conditions that may affect the kidney (e.g., Lupus, multiple myeloma) c. Subject has taken metformin (Glucophage) within 48 hours of procedure d. Subject has had a prior reaction to iodinated contrast e. Subject has multiple allergies and/ or severe asthma regularly treated with medication f. Subject has had an episode of serious allergic reaction (anaphylaxis) to any substance
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of partipicants with adverse events
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jafi Lipson, Stanford University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- BRS0031
- 27277
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast - Female
-
Stanford UniversityCompletedBreast - FemaleUnited States
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
International Research Training Group 2804German Research Foundation; Uppsala University; University Hospital TuebingenNot yet recruitingMenopause | Breast Cancer Female | Healthy Female | Anti-estrogenic TherapyGermany
-
Stanford UniversitySuspended
-
Eli Lilly and CompanyActive, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial CancerUnited States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
-
Instituto de Investigación Sanitaria de la Fundación...Lumenis Be Ltd.; Mucosa Innovations, S.L.Not yet recruitingBreast Cancer Female | Female Urogenital Diseases
-
Mayo ClinicRecruitingBreast Cancer | Breast Carcinoma | Breast Cancer FemaleUnited States
-
Wake Forest University Health SciencesCompleted
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Brigham and Women's HospitalJohns Hopkins University; Partners in Health; Rwanda Biomedical CentreRecruitingBreast Cancer | Cervix Cancer | Benign Breast DiseaseRwanda